We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.79 | -0.62% | 127.47 | 128.48 | 127.18 | 128.11 | 6,221,929 | 01:00:00 |
From May 2022 to May 2024
By Colin Kellaher
Merck & Co. on Tuesday said a Phase 3 study of its blockbuster cancer drug Keytruda met its key endpoint in certain patients with stomach cancer.
The Kenilworth, N.J., drugmaker said Keytruda combined with chemotherapy showed a statistically significant and clinically meaningful improvement in the study's primary endpoint of overall survival versus chemotherapy alone as the first-line treatment of patients with human epidermal growth factor receptor 2, or HER2, negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Merck said it also saw statistically significant and clinically meaningful improvements in progression-free survival and overall response rate.
Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors, is approved in dozens of indications around the world and had sales of nearly $15.5 billion for the first nine months of the year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 22, 2022 07:35 ET (12:35 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
